Overview

Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

Status:
Recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

In patients with coronary heart disease who were treated with PCSK9 inhibitor evolocumab for intensive lipid-lowering therapy, the changes of retinal microvessels were measured with OCTA (Optical Coherence Tomography Angiography)before and after the treatment. The specific indicators included retinal microvessel diameter, macular area，optic disc vascular density and FAZ(Foveal Avascular Zone)area, etc., to clarify the effect of evolocumab on retinal microvessels after intensive lipid-lowering therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Zibo Central Hospital

Treatments:

Evolocumab
Hydroxymethylglutaryl-CoA Reductase Inhibitors